|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
5-FU pretreatment downregulated cellular FLICE-inhibitory protein (cFLIP) and specific cFLIP downregulation by small interfering RNA was sufficient to sensitise TRAIL-resistant HCC cell lines for TRAIL-induced apoptosis.
|
15105837 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RNA interference-mediated hTERT inhibition enhances TRAIL-induced apoptosis in resistant hepatocellular carcinoma cells.
|
20204286 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined delivery of Ad/hTERT-CYLD and ZD55-TRAIL may be a new useful strategy for HCC or other tumor cells with enhanced NF-kappaB activity.
|
16627981 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated transfection of caspase-8 sensitizes hepatocellular carcinoma to TRAIL- and chemotherapeutic agent-induced cell death.
|
16750275 |
2006 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To observe the anti-liver cancer activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene and its bystander effects on hepatocellular carcinoma (HCC) cell line SMMC7721.
|
14991932 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5.
|
22400995 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that ATRA or TRAIL resistance in AFP producing hepatoma is at least, in part, attributable to the high level of the cytoplasmic AFP.
|
19267404 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL receptors on HCC cells were up-regulated by 5-FU, and IFNalpha induced TRAIL on CD4(+) T cells, CD14(+) monocytes, and CD56(+) NK cells.
|
15585621 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
|
30544063 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we constructed an adenoviral vector (designated Ad/TRAIL-F/RGD) with RGD-modified fibers, expressing the TRAIL gene from the human telomerase reverse transcriptase (hTERT) promoter, and evaluated its antitumor activity in HCC cell lines.
|
15849810 |
2005 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, experiments in both hepatocellular carcinoma and melanoma-bearing mice demonstrated that the genetically engineered rNDV-IL-2-TRAIL exhibited prolonged animals' survival compared with rNDV, rNDV-IL-2, and rNDV-TRAIL.
|
24971746 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, our findings provide evidence for the existence of a novel mechanistic link between increased TR and TRAIL levels in HCC.
|
22576662 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that TRAIL induces the hepatocellular carcinoma apoptosis associated with A20 knockdown in a concentration-dependent manner.
|
22285182 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
|
16273304 |
2005 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pretreatment with the proteasome inhibitor MG132 and PS-341 rendered TRAIL-resistant hepatocellular carcinoma (HCC) cell lines but not primary human hepatocytes sensitive for TRAIL-induced apoptosis.
|
16037944 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
|
21412282 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The transgene TRAIL expression controlled by hTERT promoter was evaluated in BEL7404 HCC cell line.
|
20213096 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We investigated the effects of combining wild-type p53 gene transduction by adenoviral infection (Ad-p53) with addition of TRAIL on cell death, expression levels of TRAIL receptors (TRAIL-R1, TRAIL-R2), FLICE inhibitory protein (FLIP) and X-linked inhibitor of apoptosis protein (XIAP) on human hepatocellular carcinoma (HCC) cell lines.
|
15254777 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, whether such change of miRNA on TRAIL sensitivity is seen in hepatocellular carcinoma still needs to be explored.
|
28410209 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fn14•TRAIL induced robust apoptosis of multiple HCC cell lines, while sparing non-malignant hepatocyte cell lines.
|
24130833 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms.
|
27154307 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the cancer stem cells (CSCs) are believed to be responsible for the treatment failure in multiple cancers including hepatocellular carcinoma (HCC), the aim of this study was to investigate the strategies to increase the sensitivity of liver cancer stem cells (LCSCs) to TRAIL.
|
27840896 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we revealed that CASC2, a well-established tumor suppressive long non-coding RNA, could serve as a "Sponge" of miR-24 and miR-221, thus modulating TRAIL-induced tumor cell apoptosis TRAIL resistance of hepatocellular carcinoma.
|
29476051 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, the results of the present study indicate that BM-MSC can provide a steady source of stTRAIL and may be suitable for use in the prevention of the recurrence of hepatocellular carcinoma after RFA with secretable trimeric TRAIL.
|
24451114 |
2014 |